Molecular signature to risk-stratify prostate cancer of intermediate risk
Y Yin, Q Zhang, H Zhang, Y He, J Huang - Clinical Cancer Research, 2017 - AACR
Y Yin, Q Zhang, H Zhang, Y He, J Huang
Clinical Cancer Research, 2017•AACRA new 30-gene signature has been described that separates prostate cancers of Gleason
score≤ 6 from those of Gleason score≥ 8. It provides independent prognostic information
for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to
stratify these patients into different risk groups. Clin Cancer Res; 23 (1); 6–8.© 2016 AACR.
See related article by Sinnott et al., p. 81
score≤ 6 from those of Gleason score≥ 8. It provides independent prognostic information
for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to
stratify these patients into different risk groups. Clin Cancer Res; 23 (1); 6–8.© 2016 AACR.
See related article by Sinnott et al., p. 81
Abstract
A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6–8. ©2016 AACR.
See related article by Sinnott et al., p. 81
AACR